DBVT Stock Analysis: Buy, Sell, or Hold?
DBVT - DBV Technologies S.A.
$14.55
0.31 (2.18%)
â˛
5d:
+3.78%
30d:
+4.98%
90d:
-21.65%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Oct 28, 2026
Get Alerted When DBVT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: DBVT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: DBVT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: DBVT is currently trading at $14.55, which is considered slightly high relative to its 30-day fair value range of $13.62 to $14.64.
Technical Outlook: Technically, DBVT is in a strong downtrend. Immediate support is located at $13.36, while resistance sits at $15.10.
Market Sentiment: DBVT scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (11th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $41.76 (+187.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DBVT is in a strong downtrend. Immediate support is located at $13.36, while resistance sits at $15.10.
Market Sentiment: DBVT scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (11th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $41.76 (+187.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$13.62 -
$14.64
Company Quality Score
41/100
(HOLD)
Options IV Signal
11th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
54.2%
All Signals
- BULLISH: Options cheap (IV 11th percentile)
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 187.0% below Wall St target ($41.76)
- WARNING: Composite score 40/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$13.62 -
$14.64
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
Âą$1.66
(11.4%)
Support & Resistance Levels
Support Level
$13.36
Resistance Level
$15.10
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-31.61
Wall Street Target
$41.76
(+187.0%)
Revenue Growth (YoY)
-53.3%
Share & Embed Analysis
Last updated: August 23, 2026 3:40 AM ET
Data refreshes hourly during market hours. Next update: 4:40 AM
Data refreshes hourly during market hours. Next update: 4:40 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DBVT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$372 | 42 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$563 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 51 HOLD |